WOVEN-PLANET-HOLDINGS
23.3.2022 05:32:09 CET | Business Wire | Press release
ENEOS Corporation (ENEOS) and Toyota Motor Corporation (Toyota) have signed a joint agreement to explore CO2 -free hydrogen production and usage at Woven City, the prototype city of the future that Toyota has started to develop in Susono City, Shizuoka Prefecture, Japan. Together with Toyota’s subsidiary Woven Planet Holdings, Inc. (Woven Planet), they will accelerate efforts by managing technical logistics.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220322006181/en/
As described in the Basic Agreement signed in 2021, ENEOS and Toyota have decided to commence construction and operation of a hydrogen refueling station in close proximity to Woven City to produce and supply CO2 -free hydrogen to Woven City and Fuel Cell Electric Vehicles (FCEVs) (Item 1 and 2 set forth below). Together, they will also research and design an efficient hydrogen supply and demand management system (Item 3 described below). The ENEOS hydrogen refueling station is scheduled to begin operations before the opening of Woven City in 2024-2025.
Items to be considered at the time of the Basic Agreement*1
- ENEOS to establish and operate a hydrogen refueling station in close proximity to Woven City
- ENEOS to produce "green hydrogen," hydrogen derived from renewable energy, by electrolyzers at the aforementioned station and supply it to Woven City to be used at a stationary fuel cell generator that will be installed within Woven City by Toyota
- Promote the use of hydrogen-powered fuel cell mobility for logistics in and nearby Woven City. Validate a base unit*2 of hydrogen demand for those mobility logistics as well as build a supply and demand management system
- Conduct joint advanced research on hydrogen supply at the demonstration hub to be established within Woven City
Items that have been decided in the joint development agreement this time
Item 1) |
- Construct a hydrogen refueling station adjacent to Woven City (Scheduled to be constructed at 1576-3, Mishuku Aza Hounokidaira, Susono-city, Shizuoka-Pref., Japan) |
Item 2) |
- Install electrolyzers at the hydrogen refueling station, which will produce CO2 -free hydrogen using electricity generated by renewable energy - Supply CO2 -free hydrogen to not only various FCEVs from passenger cars to commercial vehicles but also to Woven City using a pipeline - Install a stationary fuel cell generator at the hydrogen refueling station in case of a power outage*3 |
Item 3) |
- Consider connecting the Community Energy Management System (CEMS) of Woven City with the hydrogen EMS of ENEOS to optimize hydrogen production |
The ENEOS hydrogen refueling station will “produce” the hydrogen that will meet the energy needs of “users,” FCEVs in and around Woven City and Woven City as well. This collaboration expedites our progress toward realizing a truly carbon-neutral society and will facilitate and normalize clean energy operations first at Woven City and eventually the world.
Woven City is the project of Toyota aiming to create happiness through mobility of "people," "goods," and "information." It is focused on three pillars. That are: Human-Centered City that makes people happier in their everyday lives, considering the needs of different kinds of people before and during the development of technology; Living Laboratory, the first-of-its-kind test track for mobility where researchers, engineers, and scientists demonstrate innovative ideas and future technologies both virtually and in the real world; and Ever-Evolving City, rooted in Toyota’s kaizen (continuous improvement) approach, is focused on new ideas that provide better mobility of information, goods, and people.
*1 Announced on May 10, 2021 “ENEOS and Toyota Come Together to Make Woven City the Most Hydrogen-Based Society”
*2 Hydrogen can be supplied to FCEVs even during power outages by using stored hydrogen to operate a hydrogen refueling system with a stationary fuel cell generator. This allows the external power supply function of FCEVs to be utilized to provide power support where electricity is needed.
*3 The "base unit" is a standard of measurement required to ensure a result that is both practically valuable to users and commercially viable.
About ENEOS Corporation
Under ENEOS Holdings, Inc., the ENEOS Group has developed businesses in the energy and nonferrous metals segments, from upstream to downstream. The Group's envisioned goals for 2040 are: becoming one of the most prominent and internationally-competitive energy and materials company groups in Asia, creating value by transforming our current business structure, and contributing to the development of a low-carbon, recycling-oriented society with the pursuit of carbon-neutral status in its own CO2 emissions. ENEOS Corporation, one of the principal operating companies in the Group, is contributing to achievement of the Group's envisioned goals through a broad range of energy businesses.
https://www.hd.eneos.co.jp/english/
https://www.eneos.co.jp/english/
About Toyota Motor Corporation
Toyota Motor Corporation (Toyota) (NYSE: TM) is the global mobility company that introduced the Prius hybrid-electric car in 1997 and the first mass-produced fuel cell sedan, Mirai, in 2014. Headquartered in Toyota City, Japan, Toyota has been making cars since 1937. Today, Toyota proudly employs 370,000 employees in communities around the world. Together, they build around 10 million vehicles per year in 28 countries and regions, from mainstream cars and premium vehicles to mini-vehicles and commercial trucks, and sell them in more than 170 countries and regions under the brands Toyota, Lexus, Daihatsu and Hino.
For more information, please visit https://global.toyota/en
Woven Planet
Woven Planet is building the safest mobility in the world. A subsidiary of Toyota, Woven Planet innovates and invests in new technologies, software, and business models that transform how we live, work and move. With a focus on automated driving, smart cities, robotics and more, Woven Planet builds on Toyota's legacy of trust to deliver secure, connected, reliable, and sustainable mobility solutions for all.
Learn more at woven-planet.global.
End
View source version on businesswire.com: https://www.businesswire.com/news/home/20220322006181/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom